Venetoclax is a potent BCL-2 selective BH3-mimetic that is clinically approved for use in chronic lymphocytic leukemia and treatment of patients with acute myeloid leukemia who are aged or unmet for intensive induction chemotherapy [45]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.